Amicus Therapeutics Inc Total Assets
Amicus Therapeutics Inc total assets. Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) holds total assets worth $949.87 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see FOLD market cap for the company's overall valuation and market capitalisation.
Total Assets of Amicus Therapeutics Inc (2003–2025)
Total assets of Amicus Therapeutics Inc from 2003 to 2025. This chart illustrates how Amicus Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Amicus Therapeutics Inc stock price for real-time trading data and today's change.
Amicus Therapeutics Inc - Asset Composition Analysis
Amicus Therapeutics Inc Total Assets Breakdown (December 2025)
Amicus Therapeutics Inc total assets breakdown as of December 2025. Amicus Therapeutics Inc's total assets of $949.87 Million consist of 71.2% current assets and 28.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.5% |
| Accounts Receivable | $115.31 Million | 12.1% |
| Inventory | $228.82 Million | 24.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.91 Million | 1.5% |
| Goodwill | $197.80 Million | 20.8% |
Asset Composition Trend (2003–2025)
This chart illustrates how Amicus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Amicus Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amicus Therapeutics Inc's current assets represent 71.2% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 22.5% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 24.1% of total assets.
Amicus Therapeutics Inc Competitors by Total Assets
Key competitors of Amicus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Amicus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.84 | 3.39 | 5.05 |
| Quick Ratio | 1.88 | 2.60 | 4.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $438.35 Million | $356.03 Million | $403.24 Million |
Amicus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Amicus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.59 |
| Latest Market Cap to Assets Ratio | 4.79 |
| Asset Growth Rate (YoY) | 21.0% |
| Total Assets | $949.87 Million |
| Market Capitalization | $4.55 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Amicus Therapeutics Inc's assets at a significant premium (4.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Amicus Therapeutics Inc's assets grew by 21.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Amicus Therapeutics Inc (2003–2025)
The table below shows the annual total assets of Amicus Therapeutics Inc from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $949.87 Million | +21.00% |
| 2024-12-31 | $785.03 Million | +0.92% |
| 2023-12-31 | $777.88 Million | +7.42% |
| 2022-12-31 | $724.17 Million | -19.99% |
| 2021-12-31 | $905.14 Million | +2.10% |
| 2020-12-31 | $886.52 Million | +4.27% |
| 2019-12-31 | $850.21 Million | +7.63% |
| 2018-12-31 | $789.95 Million | +25.98% |
| 2017-12-31 | $627.02 Million | -39.53% |
| 2016-12-31 | $1.04 Billion | +14.14% |
| 2015-12-31 | $908.38 Million | +332.63% |
| 2014-12-31 | $209.97 Million | +64.60% |
| 2013-12-31 | $127.56 Million | +15.87% |
| 2012-12-31 | $110.09 Million | +57.73% |
| 2011-12-31 | $69.80 Million | -37.99% |
| 2010-12-31 | $112.55 Million | +31.84% |
| 2009-12-31 | $85.37 Million | -33.71% |
| 2008-12-31 | $128.77 Million | -22.94% |
| 2007-12-31 | $167.10 Million | +180.15% |
| 2006-12-31 | $59.65 Million | +108.04% |
| 2005-12-31 | $28.67 Million | +465.15% |
| 2004-12-31 | $5.07 Million | +912.57% |
| 2003-12-31 | $501.00K | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more